Dyne Therapeutics appoints Ranade as CBO, Batra as CSO

Dyne Therapeutics (DYN) announced the appointments of Vikram Ranade, PhD, as chief business officer, CBO, and Ranjan Batra, PhD, as chief scientific officer, CSO, of Dyne. Dr. Ranade will lead business development, corporate strategy and strategic partnerships to support the company’s late-stage clinical and commercialization plans. Dr. Batra will lead the company’s research strategy, pipeline development and activities supporting clinical development. Effective April 28, 2025, Oxana Beskrovnaya, PhD, will transition from CSO to chief innovation officer, CIO, responsible for driving Dyne’s comprehensive innovation strategy to maximize the value of its FORC platform and further enable the company’s long-term success.